<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1728-8800-2024-4170</article-id><article-id custom-type="edn" pub-id-type="custom">XHRBDO</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-4170</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ ЛИТЕРАТУРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEW ARTICLES</subject></subj-group></article-categories><title-group><article-title>Биобанки в исследованиях сердечно-сосудистых заболеваний</article-title><trans-title-group xml:lang="en"><trans-title>Biobanks in cardiovascular disease research</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3147-3025</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гусакова</surname><given-names>А. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Gusakova</surname><given-names>A. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Анна Михайловна Гусакова — к.фарм.н., с.н.с. отделения клинической лабораторной диагностики.</p><p>Томск</p></bio><bio xml:lang="en"><p>Tomsk</p></bio><email xlink:type="simple">anna@cardio-tomsk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1235-9956</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кравченко</surname><given-names>Е. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kravchenko</surname><given-names>E. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Елена Сергеевна Кравченко — м.н.с. отделения клинической лабораторной диагностики.</p><p>Томск</p></bio><bio xml:lang="en"><p>Tomsk</p></bio><email xlink:type="simple">Nikonova@cardio-tomsk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9645-6720</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Суслова</surname><given-names>Т. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Suslova</surname><given-names>T. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Татьяна Евгеньевна Суслова — к.м.н., зав. отделением клинической лабораторной диагностики.</p><p>Томск</p></bio><bio xml:lang="en"><p>Tomsk</p></bio><email xlink:type="simple">tes@cardio-tomsk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9050-4493</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Попов</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Popov</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сергей Валентинович Попов — д.м.н., академик РАН, директор.</p><p>Томск</p><p> </p></bio><bio xml:lang="en"><p>Tomsk</p></bio><email xlink:type="simple">psv@cardio-tomsk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6009-0253</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бощенко</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Boshchenko</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Алла Александровна Бощенко — д.м.н., зам. директора по научной работе.</p><p>Томск</p></bio><bio xml:lang="en"><p>Tomsk</p></bio><email xlink:type="simple">bosh@cardio-tomsk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>НИИ кардиологии — филиал ФГБНУ "Томский национальный исследовательский медицинский центр РАН"</institution></aff><aff xml:lang="en"><institution>Cardiology Research Institute — branch of the Tomsk National Research Medical Center</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>30</day><month>12</month><year>2024</year></pub-date><volume>23</volume><issue>11</issue><issue-title>Биобанкирование</issue-title><fpage>4170</fpage><lpage>4170</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Гусакова А.М., Кравченко Е.С., Суслова Т.Е., Попов С.В., Бощенко А.А., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Гусакова А.М., Кравченко Е.С., Суслова Т.Е., Попов С.В., Бощенко А.А.</copyright-holder><copyright-holder xml:lang="en">Gusakova A.M., Kravchenko E.S., Suslova T.E., Popov S.V., Boshchenko A.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/4170">https://cardiovascular.elpub.ru/jour/article/view/4170</self-uri><abstract><p>Выполнен систематический обзор научных публикаций открытой базы PubMed, eLibrary.ru, каталогов биоресурсных коллекций BBMRI-ERIC (Biobanking and Biomolecular Resources Research Infrastructure — European Research Infrastructure Consortium) и научных исследований международного регистра клинических исследований ClinicalTrials.gov на глубину 15 лет, целью которого явился поиск приоритетных направлений использования биобанков в кардиологии. Установлено, что ключевыми направлениями исследований биобанков крови и ткани сердца является изучение патогенетических механизмов возникновения и развития заболеваний сердца и сосудов, создание инновационных методов диагностики, лечения и профилактики сердечно-сосудистых заболеваний (ССЗ). Применение современных технологий, таких как геномика, транскриптомика, протеомика и метаболомика, позволяет идентифицировать кандидатные маркеры, выявлять новые молекулярные мишени для лекарственной терапии, диагностические и терапевтические подходы при ССЗ. Одним из многообещающих направлений является поиск и изучение полигенных шкал риска возникновения ССЗ и предикторов развития неблагоприятных сердечно-сосудистых событий. Анализ регистра клинических испытаний выявил еще одну важную сферу применения биобанков — клинические исследования, в рамках которых биобанки являются ключевым ресурсом образцов крови и ткани, а также клинических, социально-демографических, лабораторных и инструментальных данных. Таким образом, исследования с использованием ресурсов биобанков необходимы для изучения патогенетических механизмов ССЗ, выявления новых протеомных биомаркеров и генетических факторов, совершенствования методов диагностики, профилактики и лечения.</p></abstract><trans-abstract xml:lang="en"><p>A systematic review of publications from the PubMed and eLibrary. ru databases, Biobanking and Biomolecular Resources Research Infrastructure — European Research Infrastructure Consortium (BBMRI-ERIC) and ClinicalTrials.gov studies was carried out for 15 years. The aim was to find priority areas for the use of biobanks in cardiology. The key areas of research on blood and heart tissue biobanks are the study of pathogenetic mechanisms, creation of innovative methods for diagnosis, treatment and prevention of cardiovascular diseases (CVDs). The use of modern technologies such as genomics, transcriptomics, proteomics and metabolomics allows identifying candidate markers, revealing new molecular targets for drug therapy, diagnostic and therapeutic approaches for CVD. One of the promising areas is the search and study of polygenic scores of CVD risk and predictors of adverse cardiovascular events. Analysis of the registry revealed another important area of biobank application — clinical trials, in which biobanks are a key resource of blood and tissue samples, as well as clinical, paraclinical, and socio-demographic data. Therefore, studies using biobank resources are necessary to study the pathogenetic mechanisms of CVD, identify new proteomic biomarkers and genetic factors, as well as to improve diagnostics, prevention and treatment.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>биобанк</kwd><kwd>биобанкирование</kwd><kwd>сердечно-сосудистые заболевания</kwd><kwd>кардиология</kwd><kwd>клинические исследования</kwd><kwd>геном</kwd></kwd-group><kwd-group xml:lang="en"><kwd>biobank</kwd><kwd>biobanking</kwd><kwd>cardiovascular diseases</kwd><kwd>cardiology</kwd><kwd>clinical trials</kwd><kwd>genome</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена в рамках темы ФНИ 122020300043-1 НИИ кардиологии Томского НИМЦ</funding-statement><funding-statement xml:lang="en">The work was carried out within the topic 122020300043-1 of the Cardiology Research Institute of the Tomsk National Research Medical Center</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Бойцов С. А., Погосова Н. В., Аншелес А. А. и др. Кардиоваскулярная профилактика 2022. Российские национальные рекомендации. Российский кардиологический журнал. 2023;28(5):5452. doi:10.15829/1560-4071-2023-5452.</mixed-citation><mixed-citation xml:lang="en">Boytsov SA, Pogosova N, Ansheles AA, et al. Cardiovascular prevention 2022. Russian national guidelines. Russ J Cardiol. 2023;28(5):5452. (In Russ.) doi:10.15829/1560-4071-2023-5452.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Townsend N, Kazakiewicz D, Lucy Wright F, et al. Epidemiology of cardiovascular disease in Europe. Nat Rev Cardiol. 2022;19(2): 133-43. doi:10.1038/s41569-021-00607-3.</mixed-citation><mixed-citation xml:lang="en">Townsend N, Kazakiewicz D, Lucy Wright F, et al. Epidemiology of cardiovascular disease in Europe. Nat Rev Cardiol. 2022;19(2): 133-43. doi:10.1038/s41569-021-00607-3.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Gaidai O, Cao Y, Loginov S. Global Cardiovascular Diseases Death Rate Prediction. Curr Probl Cardiol. 2023;48(5):101622. doi:10.1016/j.cpcardiol.2023.101622.</mixed-citation><mixed-citation xml:lang="en">Gaidai O, Cao Y, Loginov S. Global Cardiovascular Diseases Death Rate Prediction. Curr Probl Cardiol. 2023;48(5):101622. doi:10.1016/j.cpcardiol.2023.101622.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Xu W, Liang X, Chen L, et al. Biobanks in chronic disease management: a comprehensive review of strategies, challenges, and future directions. Heliyon. 2024;10(11):e32063. doi:10.1016/j.heliyon.2024.e32063.</mixed-citation><mixed-citation xml:lang="en">Xu W, Liang X, Chen L, et al. Biobanks in chronic disease management: a comprehensive review of strategies, challenges, and future directions. Heliyon. 2024;10(11):e32063. doi:10.1016/j.heliyon.2024.e32063.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Coppola L, Cianflone A, Grimaldi AM, et al. Biobanking in health care: evolution and future directions. J Transl Med. 2019;17(1): 172. doi:10.1186/s12967-019-1922-3.</mixed-citation><mixed-citation xml:lang="en">Coppola L, Cianflone A, Grimaldi AM, et al. Biobanking in health care: evolution and future directions. J Transl Med. 2019;17(1): 172. doi:10.1186/s12967-019-1922-3.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Lieb W, Strathmann EA, Röder C, et al. Population-based biobanking. Genes (Basel). 2024;15(1):66. doi:10.3390/genes15010066.</mixed-citation><mixed-citation xml:lang="en">Lieb W, Strathmann EA, Röder C, et al. Population-based biobanking. Genes (Basel). 2024;15(1):66. doi:10.3390/genes15010066.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Копылова О. В., Ершова А. И., Борисова А. Л. и др. Особенности формирования клинической аннотации биообразцов. Кардиоваскулярная терапия и профилактика. 2023;22(11):3855. doi:10.15829/1728-8800-2023-3855.</mixed-citation><mixed-citation xml:lang="en">Kopylova OV, Ershova AI, Borisova AL, et al. Specifics of creating clinical abstract of biospecimens. Cardiovascular Therapy and Prevention. 2023;22(11):3855. (In Russ.) doi:10.15829/1728-8800-2023-3855.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu Y, Jackson D, Hunter B, et al. Models of cardiovascular surgery biobanking to facilitate translational research and precision medicine. ESC Heart Fail. 2022;9(1):21-30. doi:10.1002/ehf2.13768.</mixed-citation><mixed-citation xml:lang="en">Zhu Y, Jackson D, Hunter B, et al. Models of cardiovascular surgery biobanking to facilitate translational research and precision medicine. ESC Heart Fail. 2022;9(1):21-30. doi:10.1002/ehf2.13768.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Pickardt T, Niggemeyer E, Bauer UM, et al. Competence network for congenital heart defects investigators. A biobank for longterm and sustainable research in the field of congenital heart disease in Germany. Genom Proteom Bioinform. 2016;14(4):181-90. doi:10.1016/j.gpb.2016.03.003.</mixed-citation><mixed-citation xml:lang="en">Pickardt T, Niggemeyer E, Bauer UM, et al. Competence network for congenital heart defects investigators. A biobank for longterm and sustainable research in the field of congenital heart disease in Germany. Genom Proteom Bioinform. 2016;14(4):181-90. doi:10.1016/j.gpb.2016.03.003.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Scholtes VP, de Vries JP, Catanzariti LM, et al. Biobanking in atherosclerotic disease: opportunities and pitfalls. Curr Cardiol Rev. 2011;7(1):9-14. doi:10.2174/157340311795677707.</mixed-citation><mixed-citation xml:lang="en">Scholtes VP, de Vries JP, Catanzariti LM, et al. Biobanking in atherosclerotic disease: opportunities and pitfalls. Curr Cardiol Rev. 2011;7(1):9-14. doi:10.2174/157340311795677707.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Abul-Husn NS, Kenny EE. Personalized medicine and the power of electronic health records. Cell. 2019;177(1):58-69. doi:10.1016/j.cell.2019.02.039.</mixed-citation><mixed-citation xml:lang="en">Abul-Husn NS, Kenny EE. Personalized medicine and the power of electronic health records. Cell. 2019;177(1):58-69. doi:10.1016/j.cell.2019.02.039.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Small AM, O’Donnell CJ, Damrauer SM. Large-scale genomic biobanks and cardiovascular disease. Curr Cardiol Rep. 2018;20(22). doi:10.1007/s11886-018-0969-8.</mixed-citation><mixed-citation xml:lang="en">Small AM, O’Donnell CJ, Damrauer SM. Large-scale genomic biobanks and cardiovascular disease. Curr Cardiol Rep. 2018;20(22). doi:10.1007/s11886-018-0969-8.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Koch S, Schmidtke J, Krawczak M, et al. Clinical utility of polygenic risk scores: a critical 2023 appraisal. J Community Genet. 2023;14:471-87. doi:10.1007/s12687-023-00645-z.</mixed-citation><mixed-citation xml:lang="en">Koch S, Schmidtke J, Krawczak M, et al. Clinical utility of polygenic risk scores: a critical 2023 appraisal. J Community Genet. 2023;14:471-87. doi:10.1007/s12687-023-00645-z.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Nielsen JB, Thorolfsdottir RB, Fritsche LG, et al. Biobank-driven genomic discovery yields new insight into atrial fibrillation biology. Nat Genet. 2018;50(9):1234-9. doi:10.1038/s41588-018-0171-3.</mixed-citation><mixed-citation xml:lang="en">Nielsen JB, Thorolfsdottir RB, Fritsche LG, et al. Biobank-driven genomic discovery yields new insight into atrial fibrillation biology. Nat Genet. 2018;50(9):1234-9. doi:10.1038/s41588-018-0171-3.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">van Koeverden ID, Vrijenhoek JE, de Borst GJ, et al. Biobanking in carotid artery disease: translation to clinical practice. J Cardiovasc Surg (Torino). 2017;58(2):178-86. doi:10.23736/S0021-9509.17.09859-7.</mixed-citation><mixed-citation xml:lang="en">van Koeverden ID, Vrijenhoek JE, de Borst GJ, et al. Biobanking in carotid artery disease: translation to clinical practice. J Cardiovasc Surg (Torino). 2017;58(2):178-86. doi:10.23736/S0021-9509.17.09859-7.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Shah S, Henry A, Roselli C, et al. Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. Nat Commun. 2020;11:163. doi:10.1038/s41467-019-13690-5.</mixed-citation><mixed-citation xml:lang="en">Shah S, Henry A, Roselli C, et al. Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. Nat Commun. 2020;11:163. doi:10.1038/s41467-019-13690-5.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Levin MG, Tsao NL, Singhal P, et al. Genome-wide association and multi-trait analyses characterize the common genetic architecture of heart failure. Nat Commun. 2022;13(1):6914. doi:10.1038/s41467-022-34216-6.</mixed-citation><mixed-citation xml:lang="en">Levin MG, Tsao NL, Singhal P, et al. Genome-wide association and multi-trait analyses characterize the common genetic architecture of heart failure. Nat Commun. 2022;13(1):6914. doi:10.1038/s41467-022-34216-6.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Joseph J, Liu C, Hui Q, et al. Genetic architecture of heart failure with preserved versus reduced ejection fraction. Nat Commun. 2022;13(1):7753. doi:10.1038/s41467-022-35323-0.</mixed-citation><mixed-citation xml:lang="en">Joseph J, Liu C, Hui Q, et al. Genetic architecture of heart failure with preserved versus reduced ejection fraction. Nat Commun. 2022;13(1):7753. doi:10.1038/s41467-022-35323-0.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Tadros R, Zheng SL, Grace C, et al. Large-scale genome-wide association analyses identify novel genetic loci and mechanisms in hypertrophic cardiomyopathy. medRxiv. 2023. doi:10.1101/2023.01.28.23285147.</mixed-citation><mixed-citation xml:lang="en">Tadros R, Zheng SL, Grace C, et al. Large-scale genome-wide association analyses identify novel genetic loci and mechanisms in hypertrophic cardiomyopathy. medRxiv. 2023. doi:10.1101/2023.01.28.23285147.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Tucholski T, Cai W, Gregorich ZR, et al. Distinct hypertrophic cardiomyopathy genotypes result in convergent sarcomeric proteoform profiles revealed by top-down proteomics. Proc Natl Acad Sci USA. 2020;117(40):24691-700. doi:10.1073/pnas.2006764117.</mixed-citation><mixed-citation xml:lang="en">Tucholski T, Cai W, Gregorich ZR, et al. Distinct hypertrophic cardiomyopathy genotypes result in convergent sarcomeric proteoform profiles revealed by top-down proteomics. Proc Natl Acad Sci USA. 2020;117(40):24691-700. doi:10.1073/pnas.2006764117.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Zheng S, Henry A, Cannie D, et al. Genome-wide association analysis reveals insights into the molecular aetiology underlying dilated cardiomyopathy. medRxiv. 2023. doi:10.1101/2023.09.28.23295408.</mixed-citation><mixed-citation xml:lang="en">Zheng S, Henry A, Cannie D, et al. Genome-wide association analysis reveals insights into the molecular aetiology underlying dilated cardiomyopathy. medRxiv. 2023. doi:10.1101/2023.09.28.23295408.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Chou E, Pirruccello JP, Ellinor PT, et al. Genetics and mechanisms of thoracic aortic disease. Nat Rev Cardiol. 2023;20:168-80. doi:10.1038/s41569-022-00763-0.</mixed-citation><mixed-citation xml:lang="en">Chou E, Pirruccello JP, Ellinor PT, et al. Genetics and mechanisms of thoracic aortic disease. Nat Rev Cardiol. 2023;20:168-80. doi:10.1038/s41569-022-00763-0.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Klarin D, Verma SS, Judy R, et al. Genetic architecture of abdominal aortic aneurysm in the million veteran program. Circulation. 2020;142:1633-46. doi:10.1161/CIRCULATIONAHA.120.047544.</mixed-citation><mixed-citation xml:lang="en">Klarin D, Verma SS, Judy R, et al. Genetic architecture of abdominal aortic aneurysm in the million veteran program. Circulation. 2020;142:1633-46. doi:10.1161/CIRCULATIONAHA.120.047544.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Doran S, Arif M, Lam S, et al. Multi-omics approaches for revealing the complexity of cardiovascular disease. Brief Bioinform. 2021;22:bbab061. doi:10.1093/bib/bbab061.</mixed-citation><mixed-citation xml:lang="en">Doran S, Arif M, Lam S, et al. Multi-omics approaches for revealing the complexity of cardiovascular disease. Brief Bioinform. 2021;22:bbab061. doi:10.1093/bib/bbab061.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao Q, Liu R, Chen H, et al. Transcriptome-wide association study reveals novel susceptibility genes for coronary atherosclerosis. Front Cardiovasc Med. 2023;10:1149113. doi:10.3389/fcvm.2023.1149113.</mixed-citation><mixed-citation xml:lang="en">Zhao Q, Liu R, Chen H, et al. Transcriptome-wide association study reveals novel susceptibility genes for coronary atherosclerosis. Front Cardiovasc Med. 2023;10:1149113. doi:10.3389/fcvm.2023.1149113.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Li M, Parker BL, Pearson E, et al. Core functional nodes and sex-specific pathways in human ischaemic and dilated cardio-myopathy. Nat Commun. 2020;11:2843. doi:10.1038/s41467-020-16584-z.</mixed-citation><mixed-citation xml:lang="en">Li M, Parker BL, Pearson E, et al. Core functional nodes and sex-specific pathways in human ischaemic and dilated cardio-myopathy. Nat Commun. 2020;11:2843. doi:10.1038/s41467-020-16584-z.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Sim CB, Phipson B, Ziemann M, et al. Sex-specific control of human heart maturation by the progesterone receptor. Circulation. 2021;143:1614-28. doi:10.1161/CIRCULATIONAHA.120.051921.</mixed-citation><mixed-citation xml:lang="en">Sim CB, Phipson B, Ziemann M, et al. Sex-specific control of human heart maturation by the progesterone receptor. Circulation. 2021;143:1614-28. doi:10.1161/CIRCULATIONAHA.120.051921.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Patel AP, Wang M, Pirruccello JP, et al. Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a Large National Biobank. Arterioscler Thromb Vasc Biol. 2021;41(1):465-74. doi:10.1161/ATVBAHA.120.315291.</mixed-citation><mixed-citation xml:lang="en">Patel AP, Wang M, Pirruccello JP, et al. Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a Large National Biobank. Arterioscler Thromb Vasc Biol. 2021;41(1):465-74. doi:10.1161/ATVBAHA.120.315291.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Shelbaya K, Arthur V, Yang Y, et al. Large-scale proteomics identifies novel biomarkers and circulating risk factors for aortic stenosis. J Am Coll Cardiol. 2024;83(5):577-91. doi:10.1016/j.jacc.2023.11.021.</mixed-citation><mixed-citation xml:lang="en">Shelbaya K, Arthur V, Yang Y, et al. Large-scale proteomics identifies novel biomarkers and circulating risk factors for aortic stenosis. J Am Coll Cardiol. 2024;83(5):577-91. doi:10.1016/j.jacc.2023.11.021.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Gupta K, Hinkamp C, Andrews T, et al. Highlights of cardio-vascular disease prevention studies presented at the 2023 European Society of Cardiology Congress. Curr Atheroscler Rep. 2023;25:965-78. doi:10.1007/s11883-023-01164-5.</mixed-citation><mixed-citation xml:lang="en">Gupta K, Hinkamp C, Andrews T, et al. Highlights of cardio-vascular disease prevention studies presented at the 2023 European Society of Cardiology Congress. Curr Atheroscler Rep. 2023;25:965-78. doi:10.1007/s11883-023-01164-5.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Hicks MA, Hou CYC, Iranmehr A, et al. Target discovery using biobanks and human genetics. Drug Discovery Today. 2020;25(2):438-45. doi:10.1016/j.drudis.2019.09.014.</mixed-citation><mixed-citation xml:lang="en">Hicks MA, Hou CYC, Iranmehr A, et al. Target discovery using biobanks and human genetics. Drug Discovery Today. 2020;25(2):438-45. doi:10.1016/j.drudis.2019.09.014.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Hirata M, Nagai A, Kamatani Y, et al. Overview of BioBank Japan follow-up data in 32 diseases. J Epidemiol. 2017;27(3S):S22-8. doi:10.1016/j.je.2016.12.006.</mixed-citation><mixed-citation xml:lang="en">Hirata M, Nagai A, Kamatani Y, et al. Overview of BioBank Japan follow-up data in 32 diseases. J Epidemiol. 2017;27(3S):S22-8. doi:10.1016/j.je.2016.12.006.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Klarin D, Natarajan P. Clinical utility of polygenic risk scores for coronary artery disease. Nat Rev Cardiol. 2022;19(5):291-301. doi:10.1038/s41569-021-00638-w.</mixed-citation><mixed-citation xml:lang="en">Klarin D, Natarajan P. Clinical utility of polygenic risk scores for coronary artery disease. Nat Rev Cardiol. 2022;19(5):291-301. doi:10.1038/s41569-021-00638-w.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Arnold N, Koenig W. Polygenic risk score: clinically useful tool for prediction of cardiovascular disease and benefit from lipid-lowering therapy? Cardiovasc Drugs Ther. 2021;35(3):627-35. doi:10.1007/s10557-020-07105-7.</mixed-citation><mixed-citation xml:lang="en">Arnold N, Koenig W. Polygenic risk score: clinically useful tool for prediction of cardiovascular disease and benefit from lipid-lowering therapy? Cardiovasc Drugs Ther. 2021;35(3):627-35. doi:10.1007/s10557-020-07105-7.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Mega JL, Stitziel NO, Smith JG, et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet. 2015;385(9984):2264-71. doi:10.1016/S0140-6736(14)61730-X.</mixed-citation><mixed-citation xml:lang="en">Mega JL, Stitziel NO, Smith JG, et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet. 2015;385(9984):2264-71. doi:10.1016/S0140-6736(14)61730-X.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Damask A, Steg PG, Schwartz GG, et al. Patients with high genome-wide polygenic risk scores for coronary artery disease may receive greater clinical benefit from alirocumab treatment in the ODYSSEY OUTCOMES trial. Circulation. 2021;141:624-36. doi:10.1161/Circulationaha.119.044434.</mixed-citation><mixed-citation xml:lang="en">Damask A, Steg PG, Schwartz GG, et al. Patients with high genome-wide polygenic risk scores for coronary artery disease may receive greater clinical benefit from alirocumab treatment in the ODYSSEY OUTCOMES trial. Circulation. 2021;141:624-36. doi:10.1161/Circulationaha.119.044434.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Marston NA, Kamanu FK, Nordio F, et al. Predicting benefit from evolocumab therapy in patients with atherosclerotic disease using a genetic risk score results from the FOURIER trial. Circulation. 2021;141:616-23. doi:10.1161/Circulationaha.119.043805.</mixed-citation><mixed-citation xml:lang="en">Marston NA, Kamanu FK, Nordio F, et al. Predicting benefit from evolocumab therapy in patients with atherosclerotic disease using a genetic risk score results from the FOURIER trial. Circulation. 2021;141:616-23. doi:10.1161/Circulationaha.119.043805.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Marston NA, Garfinkel AC, Kamanu FK, et al. A polygenic risk score predicts atrial fibrillation in cardiovascular disease. Eur Heart J. 2023;44(3):221-31. doi:10.1093/eurheartj/ehac460.</mixed-citation><mixed-citation xml:lang="en">Marston NA, Garfinkel AC, Kamanu FK, et al. A polygenic risk score predicts atrial fibrillation in cardiovascular disease. Eur Heart J. 2023;44(3):221-31. doi:10.1093/eurheartj/ehac460.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Lu X, Liu Z, Cui Q, et al. A polygenic risk score improves risk stratification of coronary artery disease: a large-scale prospective Chinese cohort study. Eur Heart J. 2022;43(18): 1702-11. doi:10.1093/eurheartj/ehac093.</mixed-citation><mixed-citation xml:lang="en">Lu X, Liu Z, Cui Q, et al. A polygenic risk score improves risk stratification of coronary artery disease: a large-scale prospective Chinese cohort study. Eur Heart J. 2022;43(18): 1702-11. doi:10.1093/eurheartj/ehac093.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Ehret GB, Munroe PB, Rice KM, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478(7367):103-9. doi:10.1038/nature10405.</mixed-citation><mixed-citation xml:lang="en">Ehret GB, Munroe PB, Rice KM, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478(7367):103-9. doi:10.1038/nature10405.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Pirruccello JP, Bick A, Wang M, et al. Analysis of cardiac magnetic resonance imaging in 36,000 individuals yields genetic insights into dilated cardiomyopathy. Nat Commun. 2020;11:2254. doi:10.1038/s41467-020-15823-7.</mixed-citation><mixed-citation xml:lang="en">Pirruccello JP, Bick A, Wang M, et al. Analysis of cardiac magnetic resonance imaging in 36,000 individuals yields genetic insights into dilated cardiomyopathy. Nat Commun. 2020;11:2254. doi:10.1038/s41467-020-15823-7.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Kesar A, Baluch A, Barber O, et al. Actionable absolute risk prediction of atherosclerotic cardiovascular disease based on the UK Biobank. PLoS ONE. 2022;17(2):e0263940. doi:10.1371/journal.pone.0263940.</mixed-citation><mixed-citation xml:lang="en">Kesar A, Baluch A, Barber O, et al. Actionable absolute risk prediction of atherosclerotic cardiovascular disease based on the UK Biobank. PLoS ONE. 2022;17(2):e0263940. doi:10.1371/journal.pone.0263940.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Gerner C, Costigliola V, Golubnitschaja O. Multiomic patterns in body fluids: technological challenge with a great potential to implement the advanced paradigm of 3p medicine. Mass Spectrom Rev. 2020;39(5-6):442-51. doi:10.1002/mas.21612.</mixed-citation><mixed-citation xml:lang="en">Gerner C, Costigliola V, Golubnitschaja O. Multiomic patterns in body fluids: technological challenge with a great potential to implement the advanced paradigm of 3p medicine. Mass Spectrom Rev. 2020;39(5-6):442-51. doi:10.1002/mas.21612.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Dagher G. Quality matters: International standards for biobanking. Cell Prolif. 2022;55(8):e13282. doi:10.1111/cpr.13282.</mixed-citation><mixed-citation xml:lang="en">Dagher G. Quality matters: International standards for biobanking. Cell Prolif. 2022;55(8):e13282. doi:10.1111/cpr.13282.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Покровская М. С., Борисова А. Л., Метельская В. А. и др. Роль биобанкирования в организации крупномасштабных эпидемиологических исследований. Кардиоваскулярная терапия и профилактика. 2021;20(5):2958. doi:10.15829/1728-8800-2021-2958.</mixed-citation><mixed-citation xml:lang="en">Pokrovskaya MS, Borisova AL, Metelskaya VA, et al. Role of biobanking in managing large-scale epidemiological studies. Cardiovascular Therapy and Prevention. 2021;20(5):2958. (In Russ.) doi:10.15829/1728-8800-2021-2958.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Tzortzatou-Nanopoulou O, Akyüz K, Goisauf M, et al. Ethical, legal, and social implications in research biobanking: A checklist for navigating complexity. Dev World Bioeth. 2023;1-12. doi:10.1111/dewb.12411.</mixed-citation><mixed-citation xml:lang="en">Tzortzatou-Nanopoulou O, Akyüz K, Goisauf M, et al. Ethical, legal, and social implications in research biobanking: A checklist for navigating complexity. Dev World Bioeth. 2023;1-12. doi:10.1111/dewb.12411.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
